Notably, in an assay to quantify 5hmC in the genome of patients with various hematologic malignancies, levels of 5hmC in a significant proportion of patients with wild-type (WT) TET2 (and also WT TET1 and TET3) were as low as those from patients with TET2 mutations [43]. The gene discussed is TET3; the disease is hematologic disorder.